Acebutolol
The risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Dinutuximab.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.
Advertisement
Aliskiren
The risk or severity of adverse effects can be increased when Aliskiren is combined with Dinutuximab.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Dinutuximab.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Dinutuximab.
Advertisement
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Dinutuximab.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Dinutuximab.
Amlodipine
The risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.
Advertisement
Amobarbital
Amobarbital may increase the hypotensive activities of Dinutuximab.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dinutuximab.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dinutuximab.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dinutuximab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Dinutuximab.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Dinutuximab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Anthrax immune globulin human.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Dinutuximab.
Apraclonidine
The risk or severity of adverse effects can be increased when Apraclonidine is combined with Dinutuximab.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Dinutuximab.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dinutuximab.
Atenolol
The risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Dinutuximab.
Barbital
Barbital may increase the hypotensive activities of Dinutuximab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dinutuximab.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bacillus calmette-guerin substrain tice live antigen.
Belimumab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belimumab.
Benazepril
The risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dinutuximab.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.
Betaxolol
The risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Dinutuximab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Dinutuximab.
Bisoprolol
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab.
Bretylium
The risk or severity of adverse effects can be increased when Bretylium is combined with Dinutuximab.
Brimonidine
The risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.
Bumetanide
The risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dinutuximab.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.
Canagliflozin
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dinutuximab.
Captopril
The risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.
Carteolol
The risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.
Carvedilol
The risk or severity of adverse effects can be increased when Carvedilol is combined with Dinutuximab.
Chlorothiazide
The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dinutuximab.
Chlorthalidone
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.
Cilazapril
The risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.
Clevidipine
The risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Dinutuximab.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Dinutuximab.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.
Clozapine
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Clozapine.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Dinutuximab.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Dinutuximab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Dinutuximab.
Dapagliflozin
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Dinutuximab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Dinutuximab.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Dinutuximab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Dinutuximab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Dinutuximab.
Diltiazem
The risk or severity of adverse effects can be increased when Diltiazem is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dinutuximab.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dinutuximab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.
Doxazosin
The risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.
Duloxetine
Dinutuximab may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.
Enalapril
The risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.
Enalaprilat
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab.
Eplerenone
The risk or severity of adverse effects can be increased when Eplerenone is combined with Dinutuximab.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dinutuximab.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Dinutuximab.
Ethacrynate
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.
Felodipine
The risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Dinutuximab.
Fingolimod
Dinutuximab may increase the immunosuppressive activities of Fingolimod.
Fosinopril
The risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.
Furosemide
The risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Dinutuximab.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Hepatitis B Vaccine (Recombinant).
Hexobarbital
Hexobarbital may increase the hypotensive activities of Dinutuximab.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Dinutuximab.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Dinutuximab.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Dinutuximab.
Imidapril
The risk or severity of adverse effects can be increased when Imidapril is combined with Dinutuximab.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.
Indapamide
The risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Dinutuximab.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dinutuximab.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Dinutuximab.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dinutuximab.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dinutuximab.
Isoxsuprine
The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Dinutuximab.
Isradipine
The risk or severity of adverse effects can be increased when Isradipine is combined with Dinutuximab.
Labetalol
The risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.
Lacidipine
Dinutuximab may increase the hypotensive activities of Lacidipine.
Leflunomide
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Leflunomide.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Dinutuximab.
Levobunolol
The risk or severity of adverse effects can be increased when Levobunolol is combined with Dinutuximab.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dinutuximab.
Levodopa
Dinutuximab may increase the orthostatic hypotensive activities of Levodopa.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Dinutuximab.
Lisinopril
The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Dinutuximab.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.
Mannitol
The risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Dinutuximab.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Dinutuximab.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Dinutuximab.
Methohexital
Methohexital may increase the hypotensive activities of Dinutuximab.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dinutuximab.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.
Metipranolol
The risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.
Metolazone
The risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.
Metoprolol
The risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Dinutuximab.
Moexipril
The risk or severity of adverse effects can be increased when Moexipril is combined with Dinutuximab.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Dinutuximab.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Dinutuximab.
Nadolol
The risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.
Natalizumab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.
Nebivolol
The risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.
Nesiritide
The risk or severity of adverse effects can be increased when Nesiritide is combined with Dinutuximab.
Nicardipine
The risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.
Nicorandil
Nicorandil may increase the hypotensive activities of Dinutuximab.
Nifedipine
The risk or severity of adverse effects can be increased when Nifedipine is combined with Dinutuximab.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Dinutuximab.
Nimodipine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.
Nisoldipine
The risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dinutuximab.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dinutuximab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Dinutuximab.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Dinutuximab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Dinutuximab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dinutuximab.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Dinutuximab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.
Papaverine
The risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.
Penbutolol
The risk or severity of adverse effects can be increased when Penbutolol is combined with Dinutuximab.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Dinutuximab.
Perindopril
The risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Dinutuximab.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Dinutuximab.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dinutuximab.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Dinutuximab.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Dinutuximab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dinutuximab.
Pindolol
The risk or severity of adverse effects can be increased when Pindolol is combined with Dinutuximab.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Dinutuximab.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Dinutuximab.
Prazosin
The risk or severity of adverse effects can be increased when Prazosin is combined with Dinutuximab.
Primidone
Primidone may increase the hypotensive activities of Dinutuximab.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Dinutuximab.
Propranolol
The risk or severity of adverse effects can be increased when Propranolol is combined with Dinutuximab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Dinutuximab.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.
Quinapril
The risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Rabies virus inactivated antigen, A.
Ramipril
The risk or severity of adverse effects can be increased when Ramipril is combined with Dinutuximab.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Dinutuximab.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Dinutuximab.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Dinutuximab.
Riociguat
The risk or severity of adverse effects can be increased when Riociguat is combined with Dinutuximab.
Risperidone
Dinutuximab may increase the hypotensive activities of Risperidone.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Dinutuximab.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Dinutuximab.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dinutuximab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Rotavirus Vaccine.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Dinutuximab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Rubella virus vaccine.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Dinutuximab.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Salmonella typhi ty21a live antigen.
Secobarbital
Secobarbital may increase the hypotensive activities of Dinutuximab.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Dinutuximab.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dinutuximab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Dinutuximab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Dinutuximab.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Dinutuximab.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.
Terazosin
The risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Dinutuximab.
Thiamylal
Thiamylal may increase the hypotensive activities of Dinutuximab.
Thiopental
Thiopental may increase the hypotensive activities of Dinutuximab.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Dinutuximab.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Dinutuximab.
Timolol
The risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Timolol is combined with Dinutuximab.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.
Tofacitinib
Dinutuximab may increase the immunosuppressive activities of Tofacitinib.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Dinutuximab.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Dinutuximab.
Torsemide
The risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.
Trandolapril
The risk or severity of adverse effects can be increased when Trandolapril is combined with Dinutuximab.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dinutuximab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Dinutuximab.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Dinutuximab.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Verapamil
The risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Yellow Fever Vaccine.
